Sunday 25 October 2020

Sputnik V Covid-19 vaccine gets nod for clinical trials in India

- Posted on 17 October 2020

NEW DELHI, OCT 17 : The Drug Controller General of India (DCGI) has granted approval to Dr Reddy’s, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3 clinical human trials of the Sputnik V, a Covid-19 vaccine made by Russia.

On September 16, the Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories Limited had agreed to cooperate on clinical trials and distribution of Sputnik V Covid-19 vaccine in India.

Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.

Co-chairman and Managing Director of Dr Reddy’s Laboratories G.V. Prasad in a statement said “This is a significant development that allows us to commence the clinical trials in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic.” “On regulatory approval in India, RDIF shall supply to Dr Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” a statement from the Russian fund had earlier stated.

The Russian Direct Investment Fund had also said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

“The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organisations to have a diversified anti-COVID vaccine portfolio to protect their populations,” RDIF added.

Read more

Punjabupdate is the free media platform established with a view to uphold what the fourth estate stands for without making any tall claims. Our practice so far has been to be non-conformist rather than flowing with the tide. We know this is not the easy path but then it has always been so. It is credibility and independence that are dear to us and epitomise our core values. We will question what is wrong and espouse what we feel is the right cause, at the same time fully conscious that both are relative terms but we will go by the interpretations are rooted in the collective consciousness of the people. At the same time, we will not stake any claim to be moralists as that can the most difficult test to pass and we admit it.
Copyright 2020 © punjabupdate.com